Late-onset mitochondrial cardiomyopathy triggered by anticancer treatment

2Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

We report the case of a 62-year-old woman with a history of bilateral hearing impairment, who developed mitochondrial cardiomyopathy after chemotherapy. The patient underwent postoperative cisplatin chemotherapy after the surgical treatment of cervical cancer. The systolic function of her left ventricle decreased significantly. A tissue examination of the left ventricle revealed mitochondrial cardiomyopathy. Genetic testing revealed mutations in mitochondrial 3,243 A→G. Nine hundred fifty-five individual mutations were identified by next-generation sequencing. Since cardiovascular complications are the second leading cause of morbidity and mortality in patients undergoing cancer treatment, mitochondrial cardiomyopathy should be considered a potential cause of heart failure.

Cite

CITATION STYLE

APA

Yamasaki, T., Yanishi, K., Tateishi, S., Nakanishi, N., Zen, K., Nakamura, T., … Matoba, S. (2017). Late-onset mitochondrial cardiomyopathy triggered by anticancer treatment. Internal Medicine, 56(11), 1357–1361. https://doi.org/10.2169/internalmedicine.56.8076

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free